Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVIBiotechnology
-$0.15 today
- Market cap
- $2.10B
- Beta
- 0.71
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.71
Volume 1.41M
Average 2.42M
MRVI Operating Cash Flow
Cash generated by the company's core business operations during the period.
Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow turns positive
Q2 FY2026 operating cash flow was $3.99M, compared with -$10.27M a year earlier. Trailing-twelve-month operating cash flow was -$25.26M.
Context
- Operating cash flow amounted to 31.0% of revenue in FY2025, up 28.1 pp from a year earlier.
- Operating cash flow increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near $3.99M or moves back toward the trailing-twelve-month quarterly average of -$6.32M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (57.57M) USD
- Year-over-year change
- -871.2%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (57.57M) | -871.2% |
| FY2024 | 2024-12-31 | 7.47M | -94.1% |
| FY2023 | 2023-12-31 | 126.22M | -76.4% |
| FY2022 | 2022-12-31 | 535.98M | +45.4% |
| FY2021 | 2021-12-31 | 368.57M | — |
Operating Cash Flow vs competitors
How MRVI compares with its peers on the latest reported figures
- MRVI's LTM Jun 2026 operating cash flow of $25.26M is the 8th largest of the 9 companies compared; the peer median is $71.38M.
- Its year-over-year change of +19.4% is the 3rd highest of 9, against a peer median of -4.9%.
- Operating cash flow amounts to 12.1% of revenue for MRVI, versus a peer median of 18.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $492.6M | -7.8% | +39.9% | 19.0% | |
| LTM Sep 2026 | $337.6M | +34.4% | +4.7% | 27.5% | |
| LTM Jun 2026 | $134.86M | +2.1% | -12.0% | 17.2% | |
| LTM Mar 2026 | $111.84M | -35.9% | -25.0% | 69.9% | |
| LTM Mar 2026 | $90.66M | -18.5% | -5.9% | 105.1% | |
| LTM Aug 2026 | $85.25M | -2.0% | +26.6% | 9.6% | |
| LTM Sep 2026 | $57.51M | -20.3% | +114.4% | 9.2% | |
| LTM Jun 2026 | $25.26M | +19.4% | — | 12.1% | |
| LTM Mar 2026 | $17.9M | +22.3% | — | 17.9% | |
| Peer median (excluding MRVI) | $71.38M | -4.9% | +4.7% | 18.5% | |
Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 469.25M | 490.66M | (119.03M) | (259.62M) | (130.77M) |
| Depreciation & Amortization | 24.75M | 38.1M | 48.78M | 56.87M | 60.47M |
| Deferred Income Tax | 46.9M | 42.32M | 754.94M | 2.32M | (20K) |
| Stock-Based Compensation | 10.46M | 18.67M | 34.59M | 49.42M | 0 |
| Change in Working Capital | (176.63M) | (45.08M) | 97.84M | (12.61M) | (7.98M) |
| Accounts Receivables | (70.39M) | (22.27M) | 84.4M | 14.36M | 12.82M |
| Inventory | (21.57M) | 9.46M | 649K | 377K | 8M |
| Accounts Payables | 676K | (1.58M) | 5.28M | 723K | (7.35M) |
| Other Working Capital | (85.34M) | (30.69M) | 7.52M | (28.07M) | (21.45M) |
| Other Non-Cash Items | (6.16M) | (8.7M) | (690.9M) | 171.1M | 20.73M |
| Operating Cash Flow | 368.57M | 535.98M | 126.22M | 7.47M | (57.57M) |
| Capital Expenditures | (14.85M) | (17.09M) | (65.55M) | (29.66M) | (13.15M) |
| Acquisitions (Net) | 119.96M | (238.35M) | (69.62M) | 0 | (18.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 548K | (12.17M) | 12.87M | 5.34M | 0 |
| Investing Cash Flow | 105.66M | (267.61M) | (122.31M) | (24.32M) | (31.41M) |
| Debt Repayment | (6M) | (5.44M) | (5.77M) | (234.07M) | (5.44M) |
| Common Stock Issued | 1.71M | 2.36M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | (20K) | (2.08M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (154.76M) | (184.42M) | (55.3M) | 443K | (11.06M) |
| Financing Cash Flow | (159.05M) | (187.5M) | (61.09M) | (235.71M) | (16.5M) |
| Effect of Forex Changes | (88K) | 0 | 0 | 0 | (32K) |
| Net Change in Cash | 315.09M | 80.87M | (57.18M) | (252.56M) | (105.51M) |
| Free Cash Flow | 353.72M | 518.89M | 60.67M | (22.19M) | (70.72M) |
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
Intrinsic Alpha fair value
Locked
Current Price
$7.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.